Pharma Comes Home: What Reshoring Means for Risk Leaders
Reshoring pharmaceutical manufacturing is often framed as a supply chain solution. For risk leaders, it’s also a shift in exposure. Reshoring changes the risk profile companies need to manage.
For decades, pharma supply chains were optimized for efficiency. Today, that lesson is reshaping how companies think about pharma supply chains. Domestic manufacturing is no longer viewed solely as a cost issue. Increasingly, it’s becoming a strategic imperative tied to patient access, brand reputation, and business continuity — three things that land squarely on a risk leader’s desk when they fail.
The scale of dependence on international manufacturing is significant. Nearly 90% of sites manufacturing active pharma ingredients (API) for the US market are located overseas.
Efficiency created exposure
For years, the economics of pharma manufacturing favored a global model. Generic manufacturers, which fill roughly 90% of US prescriptions, operate on razor-thin margins that leave little room to invest in supply chain diversification.
That model delivers scale and affordability and concentrates risk. US pharma supply chains have become increasingly dependent on a handful of overseas manufacturing hubs.
Policy is changing the economics of resilience
Recent federal actions are designed to make domestic pharma manufacturing faster to approve, easier to permit, and more economically attractive. For risk leaders watching this space, the signal is clear: the regulatory environment is incentivizing a shift in where exposure will sit going forward.
The industry has responded. Major investments now underway include Eli Lilly, Novartis, AstraZeneca, and Johnson & Johnson, which are committing billions of dollars to new or expanded US manufacturing facilities. These investments matter because they add domestic capacity and move more operational, construction, property, workforce, environmental, and product-liability exposure onto US soil.
Reshoring is a strategy, not a switch
Reshoring isn’t simple. It demands significant capital, skilled labor, reliable raw material supply chains, and environmental permitting.
Companies increasingly view domestic manufacturing as a risk management strategy: a way to safeguard patients, protect brand reputation, and maintain continuity when the next disruption hits.
For risk leaders, this transition is both an opportunity and a new set of questions. Billions in construction activity means new property, environmental, and builders’ risk exposures. Expanded domestic operations bring workforce safety, cyber, and product liability considerations that may look different from those in an outsourced model. It also raises practical questions: Are new facilities being designed for redundancy and business continuity? Are utilities, water access, transportation, and specialized labor being considered critical dependencies? Do insurance programs reflect the company’s changing asset base and operating footprint?
The companies navigating this well will be those that bring risk management to the table early, not after the ribbon cutting because by then, many exposure decisions will have already been made.
The value for risk leaders is in understanding the existing risk to pharma companies that offshore and balancing those with the potential new risks that result from returning operations to the US. &

